top of page
  • mmahomed2

April 30, 2018

Valitor presented the its latest preclinical data at the 2018 Association for Research in Vision and Ophthalmology conference in Honolulu, HI. This report demonstrated a substantial increase in intravitreal half-life for our lead Anti-VEGF compound compared to the drugs that currently approved or in Phase III clinical trials. These results show the clear clinical benefits our products can offer for drugs that are used to treat ocular neovascular diseases.

28 views0 comments

Recent Posts

See All

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has been awarded a Phase I SBIR grant from the National Cancer Institute. This project will support validation of our platform technology to generate long-acting immunotherapies that can provi

bottom of page